Fennec Pharma Q1 Sales Surge 73% on PEDMARK Demand, Returns to Profit
FENC sits 20% above its 52-week low of $5.65.
Summary
Fennec Pharmaceuticals reported robust first-quarter results, with product sales surging 73% year-over-year to $15.11 million, driven by strong demand and increased adoption of its key product, PEDMARK. The company also achieved net income of $201,000, reversing a loss from the prior year. This performance builds on the 50% PEDMARK sales growth reported for 2025, indicating accelerating commercial momentum. The significant sales increase and return to profitability are highly material for this small-cap pharmaceutical company, validating its commercial strategy and improving its financial outlook. Traders will be watching for sustained growth in PEDMARK adoption and continued profitability in subsequent quarters.
At the time of this announcement, FENC was trading at $6.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $233.8M. The 52-week trading range was $5.65 to $9.92. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.